Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 13 | 2023 | 324 | 2.860 |
Why?
|
| Hepacivirus | 6 | 2020 | 141 | 2.770 |
Why?
|
| Hepatitis C, Chronic | 5 | 2018 | 88 | 1.920 |
Why?
|
| Endocarditis | 2 | 2022 | 29 | 1.480 |
Why?
|
| Physicians | 6 | 2023 | 470 | 1.430 |
Why?
|
| Tuberculosis | 2 | 2020 | 295 | 1.010 |
Why?
|
| Hepatitis C | 2 | 2020 | 151 | 0.990 |
Why?
|
| Coinfection | 2 | 2024 | 58 | 0.860 |
Why?
|
| Genotype | 6 | 2018 | 663 | 0.820 |
Why?
|
| Endocarditis, Bacterial | 1 | 2022 | 36 | 0.740 |
Why?
|
| Bacteremia | 1 | 2022 | 94 | 0.710 |
Why?
|
| Ribavirin | 4 | 2017 | 23 | 0.710 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2021 | 58 | 0.710 |
Why?
|
| Dibenzothiepins | 1 | 2020 | 1 | 0.690 |
Why?
|
| World Health Organization | 1 | 2020 | 34 | 0.680 |
Why?
|
| Medicine | 1 | 2021 | 57 | 0.680 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2020 | 2 | 0.670 |
Why?
|
| Communicable Diseases | 1 | 2021 | 90 | 0.670 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2020 | 20 | 0.660 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 94 | 0.630 |
Why?
|
| Adenosine Monophosphate | 5 | 2022 | 28 | 0.610 |
Why?
|
| Alanine | 5 | 2022 | 51 | 0.610 |
Why?
|
| Disease Management | 1 | 2020 | 232 | 0.590 |
Why?
|
| Humans | 43 | 2024 | 63459 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 726 | 0.570 |
Why?
|
| Sofosbuvir | 2 | 2017 | 17 | 0.570 |
Why?
|
| Influenza, Human | 1 | 2020 | 208 | 0.560 |
Why?
|
| Patient Safety | 1 | 2020 | 242 | 0.540 |
Why?
|
| Sustained Virologic Response | 1 | 2017 | 10 | 0.540 |
Why?
|
| Motivation | 1 | 2019 | 285 | 0.520 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 178 | 0.510 |
Why?
|
| Length of Stay | 1 | 2020 | 813 | 0.490 |
Why?
|
| Quality of Health Care | 1 | 2020 | 519 | 0.480 |
Why?
|
| Drug Therapy, Combination | 5 | 2018 | 465 | 0.470 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 674 | 0.450 |
Why?
|
| Viral Load | 4 | 2021 | 231 | 0.420 |
Why?
|
| Paranasal Sinuses | 1 | 2013 | 8 | 0.410 |
Why?
|
| Interferons | 1 | 2014 | 73 | 0.410 |
Why?
|
| Heroin | 1 | 2013 | 12 | 0.410 |
Why?
|
| Mouth | 1 | 2013 | 33 | 0.410 |
Why?
|
| Nose | 1 | 2013 | 28 | 0.410 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 223 | 0.400 |
Why?
|
| Stroke | 1 | 2022 | 1196 | 0.390 |
Why?
|
| HIV Infections | 1 | 2020 | 969 | 0.390 |
Why?
|
| United States | 12 | 2024 | 7846 | 0.380 |
Why?
|
| Cocaine | 1 | 2013 | 101 | 0.380 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6659 | 0.370 |
Why?
|
| Travel Medicine | 1 | 2011 | 3 | 0.360 |
Why?
|
| Proline | 3 | 2018 | 44 | 0.360 |
Why?
|
| Travel | 1 | 2011 | 42 | 0.350 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 42 | 0.350 |
Why?
|
| Ambulatory Care | 2 | 2024 | 311 | 0.350 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 21 | 0.330 |
Why?
|
| Male | 15 | 2024 | 29897 | 0.320 |
Why?
|
| Pharmacists | 1 | 2011 | 127 | 0.320 |
Why?
|
| Pandemics | 4 | 2024 | 671 | 0.300 |
Why?
|
| Ritonavir | 3 | 2023 | 18 | 0.300 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 209 | 0.300 |
Why?
|
| Aged | 10 | 2024 | 14448 | 0.300 |
Why?
|
| Adult | 13 | 2024 | 16824 | 0.260 |
Why?
|
| Female | 13 | 2024 | 32882 | 0.250 |
Why?
|
| Chloroquine | 3 | 2020 | 61 | 0.240 |
Why?
|
| Antibody Formation | 2 | 2022 | 114 | 0.220 |
Why?
|
| Betacoronavirus | 3 | 2020 | 182 | 0.210 |
Why?
|
| Interleukin-17 | 1 | 2024 | 94 | 0.210 |
Why?
|
| Azithromycin | 2 | 2020 | 32 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 327 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2024 | 187 | 0.190 |
Why?
|
| Electromagnetic Phenomena | 1 | 2021 | 5 | 0.180 |
Why?
|
| Epithelial Cells | 1 | 2024 | 390 | 0.180 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 104 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 1644 | 0.180 |
Why?
|
| Bronchi | 1 | 2021 | 81 | 0.180 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 43 | 0.180 |
Why?
|
| Middle Aged | 8 | 2024 | 17612 | 0.180 |
Why?
|
| Bronchoscopy | 1 | 2021 | 90 | 0.180 |
Why?
|
| Certification | 1 | 2021 | 54 | 0.170 |
Why?
|
| Triazines | 1 | 2020 | 17 | 0.170 |
Why?
|
| Specialization | 1 | 2021 | 81 | 0.170 |
Why?
|
| Immunity | 1 | 2021 | 107 | 0.170 |
Why?
|
| Politics | 1 | 2020 | 35 | 0.170 |
Why?
|
| Pyridones | 1 | 2020 | 40 | 0.170 |
Why?
|
| Masks | 1 | 2020 | 23 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2460 | 0.170 |
Why?
|
| Morpholines | 1 | 2020 | 89 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 24 | 0.160 |
Why?
|
| Volunteers | 1 | 2019 | 17 | 0.160 |
Why?
|
| Capnography | 1 | 2019 | 7 | 0.160 |
Why?
|
| Biopsy | 1 | 2021 | 444 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 93 | 0.160 |
Why?
|
| Tidal Volume | 1 | 2019 | 41 | 0.160 |
Why?
|
| Counseling | 1 | 2022 | 362 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2021 | 284 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 157 | 0.160 |
Why?
|
| Organizational Culture | 1 | 2020 | 110 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2021 | 568 | 0.150 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1553 | 0.150 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 158 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2022 | 512 | 0.150 |
Why?
|
| Immunity, Innate | 2 | 2022 | 796 | 0.140 |
Why?
|
| Anilides | 1 | 2018 | 18 | 0.140 |
Why?
|
| Macrocyclic Compounds | 1 | 2018 | 8 | 0.140 |
Why?
|
| Valine | 1 | 2018 | 32 | 0.140 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
|
| Carbamates | 1 | 2018 | 26 | 0.140 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 14 | 0.140 |
Why?
|
| Lactams, Macrocyclic | 1 | 2018 | 25 | 0.140 |
Why?
|
| Cyclopropanes | 1 | 2018 | 50 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 701 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 177 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 697 | 0.140 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 7 | 0.130 |
Why?
|
| Fluorenes | 1 | 2017 | 14 | 0.130 |
Why?
|
| Hospitalization | 1 | 2024 | 1364 | 0.130 |
Why?
|
| Interferon-alpha | 2 | 2015 | 103 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2018 | 127 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2017 | 54 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 435 | 0.130 |
Why?
|
| Risk Factors | 3 | 2022 | 5356 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1101 | 0.120 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 167 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 790 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 702 | 0.120 |
Why?
|
| Vaccination | 1 | 2017 | 363 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 47 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 456 | 0.110 |
Why?
|
| Plasmodium falciparum | 1 | 2017 | 245 | 0.110 |
Why?
|
| Malaria, Falciparum | 1 | 2017 | 219 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2015 | 132 | 0.110 |
Why?
|
| Head Injuries, Penetrating | 1 | 2013 | 5 | 0.100 |
Why?
|
| Skull | 1 | 2013 | 50 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2014 | 201 | 0.100 |
Why?
|
| Vietnam | 1 | 2014 | 173 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2013 | 64 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 93 | 0.100 |
Why?
|
| Nasopharynx | 2 | 2024 | 22 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 101 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2014 | 369 | 0.100 |
Why?
|
| Mass Screening | 1 | 2017 | 691 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 298 | 0.080 |
Why?
|
| Mutation | 1 | 2018 | 2609 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2022 | 379 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2024 | 2570 | 0.060 |
Why?
|
| Nasal Mucosa | 1 | 2024 | 18 | 0.050 |
Why?
|
| Candidiasis | 1 | 2024 | 51 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5684 | 0.050 |
Why?
|
| Mycoses | 1 | 2024 | 46 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 142 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 127 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2021 | 6 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 54 | 0.040 |
Why?
|
| Pregnancy | 2 | 2017 | 2334 | 0.040 |
Why?
|
| Respiratory Rate | 1 | 2019 | 15 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 21 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 276 | 0.040 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2019 | 33 | 0.040 |
Why?
|
| Respiration | 1 | 2019 | 89 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 409 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2020 | 211 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 307 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 462 | 0.040 |
Why?
|
| Quinidine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Gravidity | 1 | 2017 | 12 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 878 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 42 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 66 | 0.030 |
Why?
|
| Antimalarials | 1 | 2017 | 124 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 564 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 641 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2081 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2017 | 422 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3294 | 0.030 |
Why?
|
| Accidents, Home | 1 | 2013 | 10 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1380 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 173 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 1122 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1256 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1559 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1003 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 1409 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4693 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 6245 | 0.010 |
Why?
|